Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a molecular diagnostics company that develops, manufactures and markets technologies for tests designed to detect and analyze nucleic acid molecules (DNA or RNA). Its news flow centers on progress in molecular assay development, regulatory pathways for its Co-Dx PCR platform, intellectual property milestones, joint ventures, and capital markets activity.
Readers following CODX news can expect regular updates on the company’s point-of-care Co-Dx PCR platform, including the Co-Dx PCR Home and Co-Dx PCR Pro instruments, associated tests, and mobile app, all of which the company notes are subject to regulatory review and not yet available for sale. Recent announcements have covered clinical evaluations for the Co-Dx PCR Flu A/B, COVID-19, RSV upper respiratory multiplex test kit, preclinical and planned clinical performance studies for tuberculosis (MTB) and HPV tests on the platform, and the development of a proprietary sample preparation instrument for point-of-care use.
Co-Diagnostics also issues news about its joint ventures and international collaborations. Updates include activities of CoSara Diagnostics Pvt. Ltd. in India, such as participation in regional conferences and capacity-building workshops, and the formation of CoMira Diagnostics with Arabian Eagle Manufacturing to research, develop, manufacture, assemble, distribute and commercialize Co-Dx technologies in the Kingdom of Saudi Arabia and 18 MENA nations.
Investors and observers will find coverage of intellectual property developments, such as the grant of Australian Patent No. AU2022270084A1 for the Co-Dx PCR platform, as well as corporate and financing events disclosed through press releases and SEC filings. News items may also highlight the company’s AI business unit and presentations at industry conferences on portable, cloud-connected PCR diagnostics and AI integration. This page aggregates these updates so that users can review CODX-related announcements and regulatory communications in one place.
Co-Diagnostics (Nasdaq: CODX) announced its participation at the 17th Annual Next Generation Dx Summit from August 18-20, 2025, at the Capital Hilton in Washington, D.C. The company will showcase its Logix Smart® clinical laboratory solutions at Booth #12 and provide information about its upcoming Co-Dx PCR diagnostics platform.
The summit serves as a platform for international thought leaders in diagnostic advancement and technology innovation. Visitors can learn about CODX's pipeline of upper respiratory, tuberculosis and HPV tests planned for clinical evaluations in 2025. The company's attendance is partially funded by a World Trade Center Utah grant.
Co-Diagnostics (NASDAQ: CODX) released its Q2 2025 financial results, reporting revenue of $0.2 million, down from $2.7 million in Q2 2024, primarily due to timing of grant revenue recognition. The company posted a net loss of $7.7 million ($0.23 per share) compared to a $7.6 million loss ($0.25 per share) in Q2 2024.
Operating expenses decreased by 19.1% to $8.2 million, while cash and equivalents stood at $13.4 million. The company remains on track with its Co-Dx PCR platform development, preparing to initiate clinical evaluations for all tests before year-end, with enhanced COVID-19 test trials beginning imminently.
Co-Diagnostics (NASDAQ:CODX), a molecular diagnostics company, has scheduled its second quarter 2025 earnings release for Thursday, August 14, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET the same day.
Key executives participating in the call include CEO Dwight Egan, CFO Brian Brown, and Head of IR Andrew Benson. Investors can access the webcast through the company's IR website and join the conference call via toll-free (888-880-3330) or toll (646-357-8766) numbers. A recording will be available on the company's website for those unable to attend.
Co-Diagnostics (NASDAQ:CODX) announced its participation at WHX Kuala Lumpur, Southeast Asia's leading healthcare exhibition, from July 16-18, 2025 at MITEC. The event, expecting over 10,000 visitors from 54 countries, will serve as a platform for CODX to showcase its PCR diagnostics portfolio.
The company will promote its Co-Primers® technology and introduce its upcoming Co-Dx™ PCR platform, including the Co-Dx PCR MTB test and 8-plex Co-Dx HPV test, both scheduled for clinical evaluations later this year. The company's participation is partially supported by a grant from World Trade Center Utah.
Co-Diagnostics (NASDAQ: CODX) announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference aims to connect emerging growth companies with institutional investors. Company representatives will engage in one-on-one meetings to showcase their value proposition and introduce their upcoming Co-Dx PCR testing platform.
The company notes that their PCR platform, which includes the PCR Home™, PCR Pro™, mobile app, and associated tests, is currently pending regulatory review by the FDA and other bodies and is not yet commercially available.
Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company known for its patented diagnostic test development platform, has scheduled its first quarter 2025 earnings release for Thursday, May 8, 2025, after market close.
The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Key executives participating include:
- Dwight Egan - Chief Executive Officer
- Brian Brown - Chief Financial Officer
- Andrew Benson - Head of Investor Relations
Investors and analysts can access the event through:
- Webcast: Available on ir.codiagnostics.com (Events & Webcasts page)
- Conference Call: Toll-free (800-715-9871) or Toll (646-307-1963)
- Passcode: 1977478
A recording will be available on the company's website for those unable to attend the live session.
Co-Diagnostics (NASDAQ: CODX) reported its full-year 2024 financial results, showing a decline in revenue to $3.9 million from $6.8 million in 2023. The company's financial performance included:
- Operating expenses of $43.0 million, down 5.2% year-over-year
- Operating loss of $40.1 million
- Net loss of $37.6 million ($1.24 per share)
- Cash position of $29.7 million as of December 31, 2024
Key developments included opening new manufacturing facilities in India and South Salt Lake, and withdrawing their initial FDA 510(k) application for the Co-Dx™ PCR Pro™ Platform to submit an enhanced version. The company plans to commence clinical evaluations for tuberculosis, HPV multiplex, and upper respiratory multiplex tests later in 2025.
Co-Diagnostics (NASDAQ: CODX), a molecular diagnostics company, has scheduled its fourth quarter and full year 2024 earnings release for Thursday, March 27, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day.
Key executives participating in the call include CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson. Investors can access the webcast through the company's investor relations website and join the conference call via domestic (844-481-2661) or international (412-317-0652) lines. A recording will be available on the company's website for those unable to attend the live event.
Co-Diagnostics (CODX) has secured a significant legal victory as the United States District Court for the District of Utah granted complete dismissal of a securities class action lawsuit on March 4, 2025. The lawsuit, filed by Gelt Trading on June 15, 2020, alleged violations of Securities Exchange Act sections regarding the company's May 1, 2020 press release about its Logix Smart® COVID-19 test.
The plaintiff claimed that CODX's statement about '100% sensitivity and 100% specificity' was misleading to investors, suggesting the test was perfectly accurate. However, the Court ruled in favor of CODX, concluding that the plaintiff failed to demonstrate loss causation, as none of the three alleged corrective disclosures effectively 'corrected' the May 1 press release or impacted the stock price.
BakerHostetler, representing CODX, successfully argued that the supposedly contradictory information was already known to the market and reflected in the stock price. This dismissal allows the company to focus on its core mission of expanding global access to high-quality molecular diagnostics.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
